Clinical trial Recruiting at 2 sites Observational Ages 55 to 90

Westlake Aging Cohort: following 55+ to map aging and cognitive changes

Official title: Westlake Aging Cohort

Run by Westlake University · NCT07373444 · Data updated 2026-11-12

A large observational study in Hangzhou will follow 2,800 adults aged 55–90 to see how aging, cognition, and neurodegenerative diseases relate to biology over time.

Quick facts

Study typeObservational
Ages55 Years to 90 Years
SexAll
Enrollment2800 (estimated)
SponsorWestlake University
Academic / other
Locations2 sites (Hangzhou, Zhejiang and 1 other locations)
StatusRecruiting
StartedJune 3, 2026
Main results expectedDecember 31, 2030
Study endsDecember 31, 2031
Registry record updatedNovember 6, 2026
Trial IDNCT07373444 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 55–90 in Hangzhou, including healthy controls and those with MCI, AD, PDD, or DLB, with a willing companion and ability to complete regular assessments.

Probably not a fit

Patients unlikely to benefit are those outside the age range, unable to participate in long-term follow-up, or lacking a capable companion for assessments.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort will collect demographic, lifestyle, clinical, neuroimaging, and multi-omics data from healthy individuals and patients with MCI, AD, PDD, and DLB to build a longitudinal database. The study aims to identify molecular signatures and biomarkers linked to neurodegenerative progression and to understand mechanisms behind cognitive decline. Data will come from repeated surveys, exams, imaging, and biological samples, enabling analyses of trajectories and potential risk factors. The project is centered in Hangzhou and leverages collaboration between Westlake University and local hospitals. It does not specify an intervention; the value lies in rich, multi-omics, longitudinal characterization.

Why it matters

Potential benefit: If successful, the study could reveal biomarkers and pathways that predict cognitive decline and support early intervention strategies.

How similar studies have gone: Similar longitudinal cohorts in aging and cognition have provided valuable biomarkers and progression insights, though this study’s multi-omics integration is relatively advanced.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age between 55 and 90 years (inclusive) at baseline.
2. Availability of a companion capable of providing independent functional assessments and fluent in Chinese.
3. Willingness and ability to regularly complete required surveys and physical examinations as per study protocol.
4. MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB/PDD patients.
5. Healthy controls: CDR = 0, memory box = 0. MCI: CDR = 0.5, memory box ≥ 0.5. AD: CDR = 0.5 or 1. The DLB/PDD meets the core features of diagnosis.
6. Healthy controls exhibit no significant cognitive or functional decline. Patients with MCI have objective cognitive impairment not sufficient for an AD diagnosis. AD patients fulfill the NINCDS-ADRDA criteria. DLB/PDD patients meet their respective international consensus diagnostic criteria. Other neurodegenerative diseases meet the diagnostic criteria.

Exclusion Criteria:

1. Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy.
2. Current use of psychoactive medications or any other drugs that may affect the study.
3. Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body.
4. Participants with any other diseases that may affect the study.

Where it's running

  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang, China
    Recruiting
  • Hangzhou Third People's Hospital
    Hangzhou, Zhejiang, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.